Introduction
============

Intervertebral disc degeneration (IVDD) is a common cause of lower back pain. IVDD is a complex and multifactorial disease owing to the involvement of genetic and environmental factors in its etiology. Genetic analyses have confirmed the involvement of varied genes in the etiology of IVDD and the role of single nucleotide polymorphisms in genes, such as vitamin D receptor 1 (VDR1) \[[@b1-asj-2019-0073]\], collagen IX alleles \[[@b2-asj-2019-0073],[@b3-asj-2019-0073]\], metalloprotease-3 (MMP-3) \[[@b4-asj-2019-0073]\], aggrecan (ACAN) \[[@b5-asj-2019-0073]\], transforming growth factor-b (TGFb) \[[@b6-asj-2019-0073]\], and interleukin (IL)-1 \[[@b7-asj-2019-0073]\] are implicated in various studies.

The structural instability of disk is mainly due to the diminished production of proteoglycans in the extracellular matrix and over expression of pro-inflammatory genes and other pathological mediators \[[@b8-asj-2019-0073]-[@b10-asj-2019-0073]\]. Current treatments available for treating degenerative disk diseases are medication, physiotherapy, and surgery that do not ensure regeneration; thus, scientists worldwide have been attempting to identify strategies that involve the use of natural extracts or phytomolecules that have the potential to control IVDD and help in the regeneration of the intervertebral disc (IVD) \[[@b11-asj-2019-0073]\]. There are several natural compounds, such as resveratrol (3, 5, 4\'-trihydroxytransstilbene), a plant phenolic compound found in the skin of grapes, blueberries, raspberries, simvastatin, atorvastatin, lovastatin, Rhizoma Drynariae, naringin (Nar), etc. that have the therapeutic potential for IVD repair. This effect is attributable to their anti-inflammatory and anti-oxidant properties that in turn enhance the proliferation of nucleus pulposus (NP) cells and downregulate the effects of tumor necrosis factor-β and MMP3 gene expression, while elevating BMP-2 (bone morphogenetic protein-2), SRY-box transcription factor 6 (SOX6), ACAN, and type II collagen protein production in NP cells *in vitro*, suggesting that they provide beneficial effects in IVDD treatment \[[@b12-asj-2019-0073]-[@b14-asj-2019-0073]\].

Nar and naringenin (NG) are natural flavonoids found in citrus fruits, particularly grape fruit \[[@b15-asj-2019-0073],[@b16-asj-2019-0073]\]. These flavonoids occur as glycosides bound to sugars and constitute about 50%--80% of all flavanoids \[[@b17-asj-2019-0073]\]. NG, the aglycone of NAR \[[@b18-asj-2019-0073]\] is hydrolyzed to aglycones by enterobacteria in the large bowel before being absorbed into the gastrointestinal tract \[[@b19-asj-2019-0073]\]. It is also evident that these flavonoids are found excessively in citrus fruit herb. *Rhizoma drynariae* is a Chinese herbal plant that has the potential to perform bone healing and repair; further, it is clinically effective in relieving lower back pain symptoms \[[@b20-asj-2019-0073]\] and most back, neck, and radicular pains. Despite their promise as therapeutic agents for IVDD repair, these molecules have not yet been applied clinically in isolation or combination therapies.

Nar is a citrus flavonoid commonly found in the pericarp of citrus fruits \[[@b17-asj-2019-0073],[@b20-asj-2019-0073]\]. Numerous studies have reported the bioactivities of Nar and its potential for treating diseases. It appears to be useful in improving cardiovascular health and has potential anticancer effects \[[@b21-asj-2019-0073]\]. However, it is only in recent times that the health benefits of Nar and NG on disk have received much attention.

This study was designed to evaluate the regenerative and anti-inflammatory efficiency of known flavonoids Nar and NG *in vitro*. NP cells were isolated from the explant disk tissue and treated with different concentrations of Nar and NG individually and in combination. Our findings reveal promising effects of flavonoids in treating IVDD. However, further studies are needed before performing any clinical trials.

Materials and Methods
=====================

Nar (C~27~H~32~O~14~, Cat\#71162, Lot\# BCBQ1754) and NG (C~15~H~12~O~5~, Cat\#N5893, Lot\# BCBR3619V) were purchased from Sigma-Aldrich (St. Louis, MO, USA). The purity of the compounds was ≥95% (high-performance liquid chromatography). Nar and NG were reconstituted in dimethyl sulfoxide (DMSO, Sigma-Aldrich) to prepare a stock solution of 2 mg/mL. Dulbecco's modified eagle's medium/nutrient mixture F-12 Ham (DMEM/F12, 1:1 mixture), 10% fetal bovine serum (FBS), 0.1% collagenase type I, antibiotic antimycotic solution 100× L with 10,000 units penicillin, 100 mg streptomycin and 25 μg amphotericin B per 1 mL in 0.9% saline, 0.25% trypsinethylenediaminetetraacetic acid, centrifuge tubes (Tarsons cat\# 546041), 100 μm Nylon Mesh (Himedia, Mumbai, India; reference TCP183), and all other chemicals and reagents were analytical/culture grade reagents purchased from Himedia and Sigma-Aldrich.

1. Culture and characterization of human nucleus pulposus cells
---------------------------------------------------------------

Disk tissues were collected from disk degenerative disease patients undergoing fusion and discectomy surgeries. This study was approved by the Institutional Ethical Committee (approval no., SS/2015/IEC127). The tissues were immediately collected in 20 mL saline supplemented with antibiotics solution and transported to the laboratory at 4°C. All the procedures were conducted in a sterile environment. Tissues were washed with phosphate-buffered saline (PBS) solution repeatedly; thereafter, the NP cells were separated by slicing the disc tissue into 1 mm^3^ segments in a moist environment and digested with 0.1% collagenase type I at 37°C for 4 hours with intermittent shaking at 30-minute intervals. The reaction was then stopped with FBS. The digested mixture was then filtered through a sterile 100-μm nylon mesh and centrifuged at 1,500 rpm for 5 minutes to collect the cell pellet. The cells were washed in PBS solution repeatedly and re-suspended in DMEM F12 medium containing 10% FBS and antibiotics (prostate-specific antigen) and seeded with cell concentration density of 1×10^5^/mL into a 75-cm^2^ flask. The cells were maintained in culture flasks at 37ºC in 5% CO2 atmosphere, and the culture media was changed 2--3 times a week. Flow cytometry was performed for characterization of the NP cells using CD 24 cell surface markers. On completion of characterization, the NP cells were used for further experimentation at passage 3 \[[@b19-asj-2019-0073],[@b20-asj-2019-0073]\].

2. Treatment with naringin and naringenin
-----------------------------------------

Cultured NP cells (5×10^4^/mL) were seeded in three 12-well cell culture plates for up to 72 hours before experimentation. Various concentrations (5, 10, 20, 50, and 100 μg/mL) of Nar and NG were added to the respective group wells individually and in 1:1, 1:2, and 2:1 combinations and control cells without any drug. The NP cells were cultured for 48 hours before harvest for RNA extraction \[[@b19-asj-2019-0073]\].

3. Immunocytochemistry of nucleus pulposus cells
------------------------------------------------

Randomly selected pellets were cultured on a cover slip. Once they attained required confluency, they were fixed with 100% ethanol for 20 minutes, immunostained with primary monoclonal antibodies against collagen II and SOX6, and were incubated overnight in the dark at 4°C. Thereafter, they were counter-stained with fluorescent secondary antibody tagged to Alexa Fluor 488 for 1 hour and observed under a confocal microscope (Leica Biosystem SPE) \[[@b19-asj-2019-0073],[@b20-asj-2019-0073]\].

4. Cell viability assay or MTT assay
------------------------------------

Normal cells, that is, the HEK cell lines were plated in 96-well plates. Cells were treated with vehicle control or different doses of Nar and NG, and with combinations for 36 hours. We selected 10-μg dose with 1:1, 1:2, and 2:1 ratio in combination therapy to avoid unwanted cytotoxicity in normal cells. After 36 hours, cell viability was analyzed using the MTT assay as per the published protocol, and absorbance was recorded at 475 nm with reference to 660 nm \[[@b22-asj-2019-0073]\].

5. Labeling mitochondria with MitoTracker Dye
---------------------------------------------

Stock solution was prepared by dissolving the lyophilized MitoTrackerR product in high-quality, anhydrous DMSO to a final concentration of 1 mM. The reduced rosamine MitoTrackerR probes (M7511) are sensitive to oxidation and are thus protected from the light. Staining solution was prepared by diluting 1 mM MitoTrackerR stock solution to a final working concentration of 25--500 nM in appropriate buffer or growth factor for staining cells that are to be fixed and permeabilized.

Cells were grown on cover slips inside a petri dish filled with the DMEM-F12 culture medium with 10% FBS. Once we attained preferred confluency, the complete media was replaced with pre-warmed (37°C) media containing staining solution (i.e., MitoTrackerR probe) and incubated for 15--45 minutes in 5% CO2 incubator. After 45 minutes of incubation, the staining solution was replaced with fresh pre-warmed media containing 3.7% formaldehyde and left at 37°C for 15 minutes. After fixation, the cells were rinsed several times with 1× PBS. The fixed cells were permeabilized by incubating in buffer-containing detergent 0.02% Triton X-100 for 10 minutes and then washed with 1× PBS. The cells were then visualized under a fluorescence microscope \[[@b23-asj-2019-0073]\].

6. Total RNA isolation, cDNA synthesis, and polymerase chain reaction (quantitative polymerase chain reaction and quantitative reverse transcription-polymerase chain reaction)
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

After 48 hours, the NP cells were harvested with trypsinization, and total RNA was isolated using a Nucleopore Mini Kit (Genetix Biotech, New Delhi, India) from all 14 samples. Final RNA was eluted in 60-μL RNase free water. The concentration of RNA was determined from the optical density of the sample measured at 260 nm using nanodrop. The extracted RNA samples were analyzed for the expression of 25 genes: COL9A1, COL9A2, COL9A3, COL11A2, catechol-O-methyltransferase (COMT), THBS2 (thrombospondin 2), ACAN, COL1A1, COL11A1, 1L6, IL10, IL18R1, IL18RAP, MMP2, MMP3, MMP9, ADAMTS5 (a disintegrin and metalloproteinase with thrombospondin motifs 5), insulin-like growth factor type 1 receptor (IGF1R), secreted protein acidic and cysteine rich (SPARC), parkin (PARK2), VDR, B-cell lymphoma 2 (BCL2), IL1A, CASP3, CASP9, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a housekeeping gene. cDNA synthesis was conducted using a Verso cDNA Synthesis Kit (Thermo Fischer Scientific, Waltham, MA, USA), and the template DNA was used for gene-specific polymerase chain reaction (PCR, Simpli-Amp Thermal Cycler, Applied Biosystems; Thermo Fischer Scientific) and reverse transcription-polymerase chain reaction (RT-PCR) (QuantStudio 5, Applied Biosystems; Thermo Fischer Scientific). PCR and RT-PCR reactions were performed as per the manufacturer's instructions. Primers used in this study were designed using the online "Primer3" program (<http://bioinfo.ut.ee/primer3-0.4.0/primer3/>); the details of the primers are listed in [Table 1](#t1-asj-2019-0073){ref-type="table"}.

All PCR products were visualized on 1.5% agarose gel with 0.5 mg/mL ethidium bromide. Photographs were taken using the gel documentation system (E Gel Imager; Life Technologies, Carlsbad, CA, USA) \[[@b22-asj-2019-0073]\].

7. Molecular docking studies
----------------------------

Molecular docking studies were performed to explain the binding mode of proteins and ligands. All the compounds were docked using the AutoDock 4.2 software (Molecular Graphics Laboratory, La Jolla, CA, USA). All the molecules were docked individually in AutoDock 4.2 \[[@b24-asj-2019-0073]-[@b26-asj-2019-0073]\]. The modeled three-dimensional structure of all the proteins was imported to AutoDock 4.2 and structurally optimized by adding hydrogens to the protein allocated with kollman charges. After adding the hydrogens, the model was saved in the PDBQT format; thereafter, ligands were prepared by optimizing the torsion angles and saved in the PDBQT format. The potential binding site for all the proteins were selected by using PDBSUM (<http://www.ebi.ac.uk/pdbsum>) \[[@b24-asj-2019-0073]-[@b27-asj-2019-0073]\]. A grid was generated to identify the xyz coordinates around the binding site of the proteins individually. Lamarckian genetic algorithm (LGA) was selected for freezing docking and default parameters used in AutoDock 4.2.

8. Statistical analyses
-----------------------

All the individual results are expressed as mean±standard deviation values. The mean values of the grouped results were tested using two-way analysis of variance (ANOVA) test, evaluated with the statistical packages SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA). A *p*-value \<0.05 was accepted as statistically significant.

9. Informed consent
-------------------

This study was approved by the Institutional Ethical Board of the Sunshine Hospital and Research Centre (approval no., SS/2015/IEC127). Written informed consent was sought after providing complete study description to the subjects.

Results
=======

1. Culture of the human nucleus pulposus cells
----------------------------------------------

NP cells were successfully isolated from the degenerated IVD from the lumbar spine and were further cultured for P~0~--P~3~ generations, propagated, expanded, and characterized after the third passage ([Figs. 1](#f1-asj-2019-0073){ref-type="fig"}, [2](#f2-asj-2019-0073){ref-type="fig"}).

2. Treatment with naringin and naringenin
-----------------------------------------

Cultured NP cells (5×10^4^ cells/mL) were seeded in 12-well plates and incubated for 72 hours before the experiment. Different concentrations of Nar and NG (5, 10, 20, 50, and 100 μg/mL) were added to wells in duplicates, and combinations of both were added in 1:1 (10:10 and 20:20 μg/mL), 1:2 (10:20 μg/mL), and 2:1 (20:10 μg/mL) ratios to the respective group wells in duplicate ([Fig. 3](#f3-asj-2019-0073){ref-type="fig"}). In comparison with the individual treatments, the combinatorial treatments of Nar-NG (1:2 and 2:1 ratios) did not show much significance; however, the dosages of Nar, NG (10--50 μg/mL) individually and in combination (1:1 ratio), resulted in a significant increase as confirmed on post-PCR gel images at particular concentrations. However, no cytotoxicity was observed at 100 μg/mL, and the concentration of 20 μg/mL Nar and NG appeared most effective and was found to be the optimum dose for promoting cell proliferation.

3. Cytotoxicity studies-MTT assay
---------------------------------

We performed an MTT assay study for assessing the proliferation efficiency in the HEK-293 cell line in the presence of Nar and NG individually and in combination after 36 hours of exposure ([Fig. 4](#f4-asj-2019-0073){ref-type="fig"}). However, the results of the MTT assay suggest that Nar or NG do not induce any cytotoxicity in the HEK-293 (normal) cell line, and the cells were proliferating normally when treated with similar dosages under our study conditions.

4. Immunocytochemistry for nucleus pulposus cells
-------------------------------------------------

After treatment with 20 μg/mL Nar and NG and their combination in a 1:1 ratio, the NP cells were immunostained with primary monoclonal antibodies collagen II and SOX2 and were then counter-stained with fluorescent secondary antibody Alexa-488 mounted with DAPI (4', 6-diamidino-2-phenylindole) nuclear stain. It showed higher expression in the cells treated with Nar and NG compared than in the untreated control sample ([Fig. 5](#f5-asj-2019-0073){ref-type="fig"}).

5. Labeling mitochondria with Mitotracker dye
---------------------------------------------

After treatment with Nar and NG, the cells were loaded with Mitotracker Green FM for mitochondria staining; representative images of mitochondrial morphology are shown in [Fig. 6](#f6-asj-2019-0073){ref-type="fig"}. Thus, mitochondrial morphological changes were analyzed with and without the drug. Mitochondria in control sample, expression was reduced under oxidative stress condition in cells, suggesting disruption and depolarization of mitochondria without drug whereas in drug-treated cells it showed over expression.

6. Effect of naringin and naringenin on gene expression assessed using reverse transcription-polymerase chain reaction
----------------------------------------------------------------------------------------------------------------------

Real-time PCR followed by gel electrophoresis was used to assess the changes in the expression of 26 genes (i.e., ACAN, collagens, interleukins, MMP, ADAMTS, etc.) constituting the markers for disk and inflammation ([Fig. 7](#f7-asj-2019-0073){ref-type="fig"}). All the samples considered for RT-PCR had five concentrations each of Nar and NG (10, 25, 50, 100, and 200 μg/mL) and were used in the ratios of 1:1, 1:2, and 2:1 of both Nar and NG as combination drugs. Cells that were not given any treatment were considered as controls. The subsequent section includes an overview of the genes studied and their expression (upregulation and downregulation) as mentioned in [Table 2](#t2-asj-2019-0073){ref-type="table"}. Further, we observed changes in the gene expression of similar genes with different drug concentrations.

GAPDH was used as a housekeeping gene. The dose-dependent Nar and NG increased the expression of discogenic regeneration markers, such as collagen and ACAN. Maximal expression was observed at a concentration of 20 μg/mL, and the combination usage of 1:2 concentration showed dramatically increased gene expression. However, treatment with Nar and NG showed effectiveness toward minimal expression of inflammatory markers, such as interleukins, caspase, and MMPs ([Fig. 7](#f7-asj-2019-0073){ref-type="fig"}).

7. Heat map effect
------------------

Grouped double gradient heat map was done using two-way ANOVA. The table of rows and columns factor of untreated (control) and treated (drug) versus means of various genes (expression by RT-PCR) showed a *p*-value with statistical significance (*p*=0.0033, 0.0009). [Fig. 8](#f8-asj-2019-0073){ref-type="fig"} shows the heat map of the grouped data ([Fig. 8A](#f8-asj-2019-0073){ref-type="fig"}) with two rows and 25 columns corresponding to 25 genes (treated and untreated) ([Fig. 8B](#f8-asj-2019-0073){ref-type="fig"}) 25 genes with respect to various dosages; smallest value coded in green show higher expression, and the largest values in red show lower expression.Twoway ANOVA showed a significant *p*-value for both, the row and column factors with *p*-value \<0.001. Genes were expressed deferentially in the control and treated groups, showing either up regulation or down regulation for most genes, while other genes have shown a trend toward marginal or neutral expression levels.

8. Molecular docking interactions of naringin and naringenin
------------------------------------------------------------

Docking of NG and Nar compounds into the binding site of all the proteins was performed to estimate the binding affinity of the complex. It is a significant part of the structure-based drug design process. It is an open-source software for drug discovery and molecular docking. The structural interactions between Protein Data Bank (PDB) with two inhibitors were docked separately. Docking studies are commonly performed for predicting the binding affinities of proteins and the binding energies of their ligands. X, Y, and Z coordinates of all the PDB's were selected by using SPDBV (<http://www.expasy.org/spdbv/>). Autodock 4.2 uses binding free energy assessment to assign the best binding conformation.

A molecular docking study was performed by using AutoDock 4.2. In this docking process, the protein is set as rigid and the ligand as flexible. AutoDock uses the LGA to search for the best conformation with reference to the minimum binding energy (kcal/mol) and hydrogen bond distance between the protein and the ligand.

Molecular docking is the most extensively used method for the calculation of protein-ligand interactions. It is an efficient method to predict the potential ligand interactions. In this study, the native ligands (NG and Nar) were identified as potent different cancer inhibitors. AutoDock 4.2 uses binding free energy assessment to assign the best binding conformation. Dockings of the NG and Nar compounds are summarized in [Tables 2](#t2-asj-2019-0073){ref-type="table"} and [3](#t3-asj-2019-0073){ref-type="table"}, respectively. Both the derivatives selected for molecular docking have some collective structural features. The comparison of free energies corresponding to the binding of title compounds with target protein reveals that maximum of the compounds interact with the receptor. Almost all molecules exhibited lower free energy values, indicating more thermodynamically favored interaction.

9. Naringenin
-------------

Molecular interaction between NG with different cancer targets, calculated the docking score. The protein was downloaded from RCSB (<https://www.rcsb.org>) for docking analysis. It was found that NG made Hydrogen bond with the amino acid residue Pro221 and Thr215 of PDB ID: 1D8M, a MMP3 target with binding energy of −8.56 kcal/mol. It also shows a hydrogen bond with Ala136 and Val117 with binding energy of −7.97 kcal/mol a MMP2 protein.

Similarly, we docked with the following targets VDR, CASP9, COL1A1, COMT, ADAMTS5, MMP9, CASP3, PARK2, IGFR1R, IL18RAP, ACAN, IL181, IL6, IL10, SPARC, IL1A, and BCL2. Nar was docked against all these targets. Among these, MMP3, MMP2, VDR, CASP9, COL1A1, and COMT targets show the best binding energy of \>−7.0 kcal/mol. Except BCL2, all the other targets showed good binding energy and interactions.

10. Naringin
------------

Molecular interaction between Nar with different cancer targets, calculated the docking score. The protein was downloaded from PDB for docking analysis. Nar created a hydrogen bond with the amino acid residue Leu295, Asn297, and Asn293 of PDB ID: 2OJ9, an IGFR1R target with a binding energy of −7.10 kcal/mol. It also showed a hydrogen bond with Ala136 and Leu83 with a binding energy of −7.09 kcal/mol a MMP2 ([Table 2](#t2-asj-2019-0073){ref-type="table"}).

Similarly, we docked with the following targets: VDR, CASP9, COL1A1, COMT, ADAMTS5, MMP9, CASP3, PARK2, IGFR1R, IL18RAP, ACAN, IL181, IL6, IL10, SPARC, IL1A, and BCL2. Out of these targets IL10, IGFR1R, MMP2, IL18RAP, CASP9, MMP3, CASP3, MMP9, ADAMTS5, and ACAN only shows a binding energy of −5.0, and other targets showed less binding energy.

From the docking simulation, we observed free energy charge of binding for the protein-ligand complex. A possible explanation may be that the radiographical structure of the protein from crystals differs from that of the aqueous system. The total energy was calculated for both the compounds against different targets shown in the [Tables 2](#t2-asj-2019-0073){ref-type="table"} and [3](#t3-asj-2019-0073){ref-type="table"}. Therefore, it can be concluded that the interaction of Nar and NG with the corresponding targets is hydrophobic interactions in nature. Molecular docking indicated that the distance of hydrogen bonding between the ligand and the protein, respectively.

AutoDock 4.2 uses binding free energy assessment to assign the best binding conformation. Experimental activities and predicted values by LGA. Dockings of the Nar and NG compounds are summarized in [Table 2](#t2-asj-2019-0073){ref-type="table"} and [Table 3](#t3-asj-2019-0073){ref-type="table"}, respectively.

Discussion
==========

The present study systematically studied the effects of Nar and NG on explant disk tissue and evaluated their potency in alleviating the disease condition by enhanced NP cells proliferation in the disk tissue. Further, the mechanisms of action of Nar and NG in IVDD were understood by the specific gene expression among variably considered genes for our research. Based on the above findings and our knowledge on Nar and NG as important natural drugs available, we decided to characterize the ratio of Nar/NG on NP cells regeneration in patients with IVDD.

Characterization of the NP cells was performed using flow cytometry (i.e., using CD24 marker). Immunocytochemistry studies were also performed where the NP cells were characterized subsequently using type II collagen and SOX2 antibody counter-stained with DAPI nuclear stain, showing higher expression in cells treated with Nar and NG than in untreated cells ([Figs. 2](#f2-asj-2019-0073){ref-type="fig"}, [5](#f5-asj-2019-0073){ref-type="fig"}). Our results showed that Nar and NG appear to enhance the proliferation of human NP cells in a dose-dependent manner independently (i.e., 5, 10, 20, 50, and 100 μg/mL). All these concentrations showed varied effectiveness with the type of gene involved, with a majority being noticed as having beneficial effects. The concentration of 5 μg/mL was too low to show its effect in cells and that of 100 μg/mL was too high and caused cell apoptosis; thus, the optimum dosages of 10 μg/mL and 50 μg/mL had the highest influence on cell proliferation ([Fig. 4](#f4-asj-2019-0073){ref-type="fig"}).

Mitochondrial morphological changes were also analyzed with and without drug treatment. Mitochondrial expression in the control sample was reduced under oxidative stress conditions in the cells, suggesting disruption and depolarization of the mitochondria without drug; however, the mitochondria were over-expressed in the drug-treated cells ([Fig. 6](#f6-asj-2019-0073){ref-type="fig"}). Up regulation of discogenic markers and down regulation of inflammatory markers was noticed in the NP cells. We observed that treatment with these drugs effectively diminished the inflammatory cytokine expression individually and in combination. Further, the expression of elevated disk markers was obvious after Nar and NG treatment, indicating repair and regeneration of the NP cells in the disk tissue ([Fig. 7](#f7-asj-2019-0073){ref-type="fig"}).

RT-PCR results showed that the genes responsible for pro-inflammation, such as interleukins, caspases, and MMPs, were down regulated, while those with functions of discogenesis, bone repair, and collagen formation (such as collagen and ACAN) were well expressed, suggesting an overall beneficial effect of these flavonoids ([Fig. 8A](#f8-asj-2019-0073){ref-type="fig"}, [B](#f8-asj-2019-0073){ref-type="fig"}).

We further studied molecular docking to confirm the binding efficiency and dissociation constants for both Nar and NG. This is important because computational and bioinformatics tools are the most extensively used methods for calculating protein-ligand interactions \[[@b26-asj-2019-0073]\]. This is an efficient method to predict potential ligand interactions. In this study, the native ligands (Nar and NG) were identified as potent inhibitors of inflammation. Both the derivatives selected for molecular docking have some collective structural features. The comparison of free energies corresponding to the binding of title compounds with the target protein reveals that most of the compounds interact with the receptor. Almost all the molecules exhibited lower free energy values, indicating more thermodynamically favored interactions ([Figs. 9](#f9-asj-2019-0073){ref-type="fig"}, [10](#f10-asj-2019-0073){ref-type="fig"}).

Conclusions
===========

Our study revealed that the use of these flavonoids to inhibit the function of inflammatory cytokines using virtual screening is an important consideration. In contrast, inhibitory constant energy and energy binding levels of certain disc markers suggested a repair mechanism to regenerate NP cells.

The present study clearly shows that citrus flavonoids are useful for improvement of inter vertebral disc properties. Further, it is noted that elevated discogenic markers expression was evident after Nar and NG treatment that indicates repair and regeneration of the NP cells in the disc tissue. We studied the expression profile of various genes using RT-PCR that revealed deferentially up-regulated and down-regulated genes. The binding efficiency of these genes to flavonoids, such as Nar and NG, were confirmed in molecular docking studies that identified them as having potent anti-inflammatory properties that improved their clinical treatment efficacy. Thus, they should be recommended for use in the treatment of patients with lumbar problems.
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![Culture of human nucleus pulposus cells from degenerated intervertebral disc. (A) Day 0: explant from the degenerated disk; (B) day 7: cells propagating out from the explants and; (C) day 21: culture flask became fully confluent. The cells were polygonal in shape like chondrocytes.](asj-2019-0073f1){#f1-asj-2019-0073}

![(A--C) Characterization of NP cells using CD24 marker on flow cytometer analysis. NP, nucleus pulposus.](asj-2019-0073f2){#f2-asj-2019-0073}

![Effect of naringin and naringenin as well as their combination on NP cells at various concentrations, including 5, 10, 20, 50, and 100 μg/mL and the combination of naringin and naringenin in the following three ratios: 1:1, 1:2, and 2:1 compared to control. We examined the growth enhancement effect of naringin and naringenin on NP cells. NP, nucleus pulposus.](asj-2019-0073f3){#f3-asj-2019-0073}

![MTT assay for assessing the cytotoxicity of individual and combinatorial flavonoid treatments in normal cell line (HEK 293).](asj-2019-0073f4){#f4-asj-2019-0073}

![Immunocytochemistry of NP cells stained with type II collagen and SOX2 (SRY-box transcription factor 6) antibody counterstained with DAPI (4', 6-diamidino-2-phenylindole) nuclear stain visualized under confocal laser scanning microscope. (A) Untreated controls, (B) naringin (20 μg/mL), (C) naringenin (20 μg/mL), and (D) naringin+naringenin (1:1 ratio). Cross-section analyses along the flattened Np cells showing a width of cell fluorescent intensity histogram visualized using confocal microscopy. (E) Np cells after drug treatment, (F) depth coding, (G) histogram image, and (H) three-dimensional topographical image. NP, nucleus pulposus.](asj-2019-0073f5){#f5-asj-2019-0073}

![Mitochondria stained with Mitotracker Green, showing mitochondria distribution using fluorescent microscope. (A) Control. (B) Naringin. (C) Naringenin. (D) Naringin+naringenin.](asj-2019-0073f6){#f6-asj-2019-0073}

![Gene expression pattern of 25 genes with different concentration of drug using gel electrophoresis. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; ACAN, aggrecan; ADAMTS5, a disintegrin and metalloproteinase with thrombospondin motifs 5; IGFR, insulin-like growth factor receptor; IL, interleukin; COL, collagen; CASP, caspase; MMP, matrix metalloproteinase; COMT, catechol-O-methyltransferase; SPARC, secreted protein acidic and cysteine rich; THBS2, thrombospondin 2; BCL2, B-cell lymphoma 2; PARK2, parkin; VDR, vitamin D receptor.](asj-2019-0073f7){#f7-asj-2019-0073}

![(A) Trend line between the control and treated groups vs. that in different genes. Gene Expression of 25 discogenic genes involved in intervertebral disc. (B) Heat map effect between the control and treated group (different concentrations) vs. that in different genes. THBS2, thrombospondin 2; BCL2, B-cell lymphoma 2; VDR, vitamin D receptor; PARK2, parkin; COMT, catechol-O-methyltransferase; SPARC, secreted protein acidic and cysteine rich; IGFR, insulin-like growth factor receptor; ADAMTS5, a disintegrin and metalloproteinase with thrombospondin motifs 5; MMP, matrix metalloproteinase; CASP, caspase; IL, interleukin; COL, collagen; ACAN, aggrecan; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.](asj-2019-0073f8){#f8-asj-2019-0073}

![(A, B) Molecular docking conformations of naringin and naringenin with aggrecan and interleukin 1 alpha.](asj-2019-0073f9){#f9-asj-2019-0073}

![Molecular docking conformations among naringin, naringenin, and proteins. ACAN, aggrecan; ADAMTS5, a disintegrin and metalloproteinase with thrombospondin motifs 5; BCL, B-cell lymphoma; CASP, caspase; COL, collagen; COMT, catechol-O-methyltransferase; IGF1R, insulin-like growth factor type 1 receptor; IL, interleukin; MMP, matrix metalloproteinase; PARK2, parkin; VDR, vitamin D receptor. (Continued to the next page).](asj-2019-0073f10){#f10-asj-2019-0073}

###### 

List of hypothetical genes involved in intervertebral disc disease

  No.                                         Genes     Gene name                                                          Sequence (5'\>-3')        Temperature (°C)   Functions
  ------------------------------------------- --------- ------------------------------------------------------------------ ------------------------- ------------------ --------------------------------------------------------
  1                                           ACAN      Aggrecan                                                           CCCCTGCTATTTCATCGACCC     64.5               Resist compressive loads on tissue
                                                                                                                           GACACACGGCTCCACTTGAT      62.5               
  2                                           ADAMTS5   A disintegrin and metalloproteinase with thrombospondin motifs 5   GAACATCGACCAACTCTACTCCG   64.6               Pathogenesis of human osteoarthritis
                                                                                                                           CAATGCCCACCGAACCATCT      62.5               
  3                                           BCL2      B-cell lymphoma 2                                                  GGTGGGGTCATGTGTGTGG       64.5               Pro-apoptotic, anti-apoptotic
                                                                                                                           CGGTTCAGGTACTCAGTCATCC    64.5               
  4                                           CASP3     Caspase 3                                                          CATGGAAGCGAATCAATGGACT    60.8               Apoptosis
                                                                                                                           CTGTACCAGACCGAGATGTCA     62.6               
  5                                           CASP9     Caspase 9                                                          CTCAGACCAGAGATTCGCAAAC    62.7               Apoptosis
                                                                                                                           GCATTTCCCCTCAAACTCTCAA    60.8               
  6                                           COL1A1    Collagen I alpha 1                                                 GAGGGCCAAGACGAAGACATC     64.5               Rigidity and elasticity
                                                                                                                           CAGATCACGTCATCGCACAAC     62.6               
  7                                           COL9A1    Collagen IX alpha 1                                                GGCAGTAGAGGAGAATTAGGACC   64.6               Delay onset of osteoarthritis
                                                                                                                           GTTCACCGACTACACCCCTG      64.5               
  8                                           COL9A2    Collagen IX alpha 2                                                CTCGCTCTGGCGCAGATTAG      64.5               Cartilage and bone ossification
                                                                                                                           GCCCATTGTCACCGTCGAT       62.3               
  9                                           COL9A3    Collagen IX alpha 3                                                GTGGATGGTCTGACTGGACG      64.5               Cartilage and bone ossification
                                                                                                                           GGGCAGATACTTGGGCACTG      64.5               
  10                                          COL11A1   Collagen XI alpha 1                                                TAACATCGCTGACGGGAAGTG     62.6               Ossification, prevent disc bulging
                                                                                                                           CCGTGATTCCATTGGTATCAACA   61.0               
  11                                          COL11A2   Collagen XI alpha 2                                                TCTTTGGTGCCCGTATTCTGG     62.6               Cartilage ossification
                                                                                                                           TGGGGTTCCTGATTTTGTGGC     62.6               
  12                                          COMT      Catechol-O-methyltransferase                                       GAAGGGGACAGTGCTACTGG      64.5               Inactivation of the catecholamine neurotransmitters
                                                                                                                           CAGGAACGATTGGTAGTGTGTG    62.7               
  13                                          IGF1R     Insulin-like growth factor type 1 receptor                         AGGATATTGGGCTTTACAACCTG   61.0               Hypertrophy of muscle and tissue
                                                                                                                           GAGGTAACAGAGGTCAGCATTTT   61.0               
  14                                          IL1A      Interleukin 1a                                                     AGATGCCTGAGATACCCAAAACC   62.8               Inflammatory cytokine
                                                                                                                           CCAAGCACACCCAGTAGTCT      62.5               
  15                                          IL6       Interleukin 6                                                      ACTCACCTCTTCAGAACGAATTG   61.0               Pro-inflammatory cytokine
  Anti-inflammatory myokine                                                                                                                                             
                                                                                                                           CCATCTTTGGAAGGTTCAGGTTG   62.8               
  16                                          IL10      Interleukin 10                                                     GACTTTAAGGGTTACCTGGGTTG   62.8               Anti-inflammatory cytokine
                                                                                                                           TCACATGCGCCTTGATGTCTG     62.6               
  17                                          IL18R1    Interleukin 18 receptor 1                                          CCTTGACCCTTTGGGTGCTTA     62.6               Pro-inflammatory
  Interleukin-18-mediated signaling pathway                                                                                                                             
                                                                                                                           CTCATGTGCAAGTGAACACGA     60.6               
  18                                          IL18RAP   Interleukin 18 receptor accessory protein                          ACCTGCCCTTCATGGGTAGTA     62.6               Cell-mediated immunity
                                                                                                                           CCCCTGGGGTCAAAAAGTGA      62.5               
  19                                          MMP2      Matrix metalloproteinase 2                                         GATACCCCTTTGACGGTAAGGA    62.7               Degradation of the disc matrix
                                                                                                                           CCTTCTCCCAAGGTCCATAGC     64.5               
  20                                          MMP3      Matrix metalloproteinase 3                                         CGGTTCCGCCTGTCTCAAG       64.5               Breakdown of extracellular matrix
                                                                                                                           CGCCAAAAGTGCCTGTCTT       60.2               
  21                                          MMP9      Matrix metalloproteinase 9                                         GGGACGCAGACATCGTCATC      64.5               Degradation of the extracellular matrix
                                                                                                                           TCGTCATCGTCGAAATGGGC      62.5               
  22                                          PARK2     Parkin                                                             GTGTTTGTCAGGTTCAACTCCA    60.8               Targeting of proteins for degradation
                                                                                                                           GAAAATCACACGCAACTGGTC     60.6               
  23                                          SPARC     Secreted protein acidic and cysteine rich                          CCCATTGGCGAGTTTGAGAAG     62.6               Mineralization and promoting mineral crystal formation
                                                                                                                           CAAGGCCCGATGTAGTCCA       62.3               
  24                                          THBS2     Thrombospondin                                                     ATAGACAGCTTCGCTCTGGAC     62.6               Cell adhesion and migration
                                                                                                                           CAAACCCCTGAAGTGACTCTC     62.6               
  25                                          VDR       Vitamin D receptor                                                 TCTCCAATCTGGATCTGAGTGAA   61.0               Normal bone mineralization and remodeling
                                                                                                                           GGATGCTGTAACTGACCAGGT     62.6               Resist compressive loads on tissue

###### 

Molecular docking interactions of naringin with their binding energy

  Gene name   PDB ID   Interacting amino acids                  Grid X-Y-Z coordinates      Binding energy ΔG (kcal/mol)   Dissociation constant (kl) (µM)
  ----------- -------- ---------------------------------------- --------------------------- ------------------------------ ---------------------------------
  IL10        2ILK     Lys117, Ser118, Lys119                   22.601, 40.659, 43.545      -4.16                          889.49
  COL1A1      3EJH     Arg552, Lys554, Arg967                   -23.600, 17.974, -4.216     -3.15                          4.89 mM
  BCL2        4AQ3     Trp103, Asn151(2), Val101                -28.353, 15.626, -21.45     -4.42                          572.84
  CASP3       2C2O     Asp2(2), Trp214, Asn208, Glu146          37.644, 25.480, 23.831      -5.65                          72.16
  CASP9       2AR9     \-                                       18.979, 34.366, -14.505     -5.67                          69.52
  COMT        3A7E     Asp44, Tyr200, Arg201                    -20.385, 14.881, 13.606     303.56                         \-
  IGFR1R      2OJ9     Leu295, Asn297, Asn293                   1.028, -2.661, 12.226       -7.1                           6.2
  IL1A        1IRA     Lys109(2), Lys111, Glu94                 46.907, 7.065, 57.268       -3.75                          1.78 mM
  IL6         1ALU     Gly77, Ser76                             -17.612, -13.109, 7.459     -3.53                          2.59 mM
  IL18RAP     3WO4     Glu32, Thr21, Glu22                      -45.056, -2.620, -25.058    -5.95                          43.53
  IL181       4R6U     His1030, Lys1120, Cys1029, Glu995        274.429, -35.631, 115.918   -3.74                          1.83 mM
  MMP2        1HOV     Ala136, Leu83                            7.840, 20.181, 15.297       -7.09                          6.33
  MMP3        4D8M     Ala167(3)                                66.413, 77.078, 37.874      -5.67                          69.5
  MMP9        1GKD     Asp410, Ala191, His411                   6.214, 47.409, -17.281      -5.42                          107.12
  PARK2       5C1Z     Lys161                                   -21.821, 23.775, 18.419     -3.74                          1.8 mM
  SPARC       2V53     Ile226(3), Leu266                        12.436, 30.887, 29.607      -3.65                          2.11
  VDR         5GT4     Lys240, Gln239                           -9.061, -10.888, 29.360     -3.87                          1.45
  ACAN        4MD4     Lys111, Glu88                            26.646, 30.740, -5.433      -5.07                          191.53
  ADAMTS5     3HYG     Val384, Ala382, His420, Thr378, Ser419   15.531, -1.503, 1.836       -5.28                          134.02

PDB, Protein Data Bank; IL, interleukin; COL1A1, collagen I alpha 1; BCL2, B-cell lymphoma 2; CASP, caspase; COMT, catechol-O-methyltransferase; IGF1R, insulin-like growth factor type 1 receptor; MMP, matrix metalloproteinase; PARK2, parkin; SPARC, secreted protein acidic and cysteine rich; VDR, vitamin D receptor; ACAN, aggrecan; ADAMTS5, a disintegrin and metalloproteinase with thrombospondin motifs 5.

###### 

Molecular docking interactions of naringenin with their binding energy

  Gene name   PDB ID   Interacting amino acids        Grid X-Y-Z coordinates      Binding energy ΔG (kcal/mol)   Dissociation constant (kl) (µM)
  ----------- -------- ------------------------------ --------------------------- ------------------------------ ---------------------------------
  IL10        2ILK     Arg110, Lys117                 22.601, 40.659, 43.545      -5.14                          171.8
  COL1A1      3EJH     Tyr525, Leu963                 -23.600, 17.974, -4.216     -7.19                          5.38
  BCL2        4AQ3     Asp150,Glu159                  -28.353, 15.626, -21.45     -4.44                          553.93
  CASP3       2C2O     Asn208, Trp214, Glu248, Asp2   37.644, 25.480, 23.831      -6.07                          78.29
  CASP9       2AR9     \-                             18.979, 34.366, -14.505     -7.79                          2.06
  COMT        3A7E     Arg201, Val42                  -20.385, 14.881, 13.606     -7.16                          5.63
  IGFR1R      2OJ9     His1030, Asn1028, Thr998       1.028, -2.661, 12.226       -5.87                          50.15
  IL1A        1IRA     Leu35, Gln20                   46.907, 7.065, 57.268       -5.05                          72.15
  IL6         1ALU     \-                             -17.612, -13.109, 7.459     -5.28                          134.36
  IL18RAP     3WO4     Arg113, Glu122, Arg123         -45.056, -2.620, -25.058    -5.86                          50.63
  IL181       4R6U     Gly252, Leu295                 274.429, -35.631, 115.918   -5.33                          124.08
  MMP2                 Ala136, Val117                 7.840, 20.181, 15.297       -7.97                          1.45
  MMP3        1D8M     Pro221, Thr215                 66.413, 77.078, 37.874      -8.56                          535.28 nM
  MMP9        1GKD     Leu114, Asp410, Ala191         6.214, 47.409, -17.281      -6.62                          14.13
  PARK2       5C1Z     Arg163, Thr83, Val456          -21.821, 23.775, 18.419     -5.99                          170.24
  SPARC       2V53     Lys282, Asp222, Asp267         12.436, 30.887, 29.607      -5.14                          170.24
  VDR         5GT4     Asp144, Ser278, Thr236         -9.061, -10.888, 29.360     -7.80                          1.91
  ACAN        4MD4     \-                             26.646, 30.740, -5.433      -5.71                          65.01
  ADAMTS5     3HYG     Ala382, Ser315                 15.531, -1.503, 1.836       -6.71                          12.08

PDB, Protein Data Bank; IL, interleukin; COL1A1, collagen I alpha 1; BCL2, B-cell lymphoma 2; CASP, caspase; COMT, catechol-O-methyltransferase; IGF1R, insulin-like growth factor type 1 receptor; MMP, matrix metalloproteinase; PARK2, parkin; SPARC, secreted protein acidic and cysteine rich; VDR, vitamin D receptor; ACAN, aggrecan; ADAMTS5, a disintegrin and metalloproteinase with thrombospondin motifs 5.
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